Figure 3 and Figure 4 show the 5-year OS and CSS rates according to the cancer stage. Five-year OS rates were shown to be significantly lower in stage I (71.2% vs. 80.0%, p = 0.020) and stage III (53.7% vs. 64.1%, p = 0.019) in the patients with high r-CEA (Figure 3). In terms of 5-year CSS rates, only stage III was shown to be significantly lower in the high r-CEA group (60.1% vs. 66.8%, p = 0.035) (Figure 4). Here, CEACAM5 is linked to cancer.